Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
High-impact trials with genetic and -omics information focus on cancer mutations, are industry-funded, and less transparent — Luigi Russo (2025) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
High-impact trials with genetic and -omics information focus on cancer mutations, are industry-funded, and less transparent
Shared by
John P A Ioannidis
Stanford University
High-impact trials with genetic and -omics information focus on cancer mutations, are industry-funded, and less transparent
Article
2025
en
Authors
+3 more
LR
Luigi Russo
LS
Leonardo Maria Siena
SF
Sara Farina
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Preprint
2024
High-Impact Trials with Genetic and -Omics Information Focus on Cancer Mutations, are Industry-Funded and Less Transparent
Luigi Russo
,
Leonardo Maria Siena
,
Sara Farina
,
Roberta Pastorino
,
Stefania Boccia
,
John P A Ioannidis
Preprint
2024
Genetic and other omics-based information in the most-cited recent clinical trials
Luigi Russo
,
Leonardo Maria Siena
,
Sara Farina
,
Roberta Pastorino
,
Stefania Boccia
,
John P A Ioannidis
Article
2012
Perceived information gain from randomized trials correlates with publication in high–impact factor journals
Εvangelos Εvangelou
,
Konstantinos Siontis
,
Thomas Pfeiffer
,
John P A Ioannidis
Article
2022
Alcohol and cancer risk, with focus on moderate drinkers
Carlo La Vecchia
,
Claudio Pelucchi
Article
2014
29: Alcohol and cancer risk, with focus on low doses
Carlo La Vecchia
Discussion(0)
No comments yet. Be the first to comment.